CD274 and non-small cell lung carcinoma: To augment the life expectancy of patients presently grappling with NSCLC, there has been a paradigm shift in contemporary clinical interventions toward a strategy that synergizes chemoradiotherapy with PD-1/PD-L1 inhibitors.